BDXNYSE
Becton, Dickinson and Company
$
0.000.00%
15-min delay
Open$
Prev Close$
Market Cap$39.53B
P/E (TTM)37.08
EPS$11.316314
EarningsJul 30, 2026
DAY RANGE
$0.00$0.00
Key Statistics
Full Stats
Market Cap$39.53B
Enterprise Value$56.56B
P/E Ratio (TTM)37.08
P/S Ratio1.93
P/B Ratio1.67
Forward P/E
EPS (TTM)$3.94
EPS (FY)$11.32
Revenue (TTM)$21.36B
Profit Margin6.61%
Operating Margin15.24%
ROE6.54%
Debt/Equity0.72
Avg Vol (30d)3.3M
Beta (1Y)0.72
Beta (3Y)0.09
Beta (5Y)0.23
Shares Out275.54M
Float275.01M
Dividend2.87%
Next EarningsJul 30, 2026
Short Interest
52-Week Range
$0.00
$127.54$187.35

Latest News
All
Company Info

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.

Websitebd.com
SectorHealth Technology
Employees70000
Phone201 847 6800
Address1 Becton Drive
Franklin Lakes, NJ, 07417-1880
ISINUS0758871091
1 Becton Drive, Franklin Lakes, NJ
Open in Maps
Analyst Consensus